Use of a nucleoside compound in the preparation of poxvirus-related products

By developing specific nucleoside compounds, the problem of monkeypox virus lacking effective drugs has been solved, efficient inhibition and treatment of monkeypox virus has been achieved, higher activity and bioavailability have been demonstrated, and the production process has been simplified.

CN117599063BActive Publication Date: 2024-11-15SHENZHEN ANTIV PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311359781.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-18
Publication Date
2024-11-15
Estimated Expiration
2043-10-18

AI Technical Summary

Technical Problem

There are no effective anti-monkeypox virus drugs in the world. The effectiveness of existing smallpox treatment drugs on monkeypox has not been verified. Monkeypox virus infection has led to a shortage of drugs, and new antiviral drugs are urgently needed.

Method used

Develop a nucleoside compound for the preparation of nucleoside compounds with inhibitory viral activity for poxvirus-related products, including specific compound structures and isomers, hydrates, solvates and pharmaceutically acceptable Salt, used to prevent, alleviate or treat diseases caused by poxvirus.

Benefits of technology

This nucleoside compound has shown higher activity than existing drugs in experiments, especially the inhibitory effect of monkeypox virus 10-26 times, has good pharmacopolytic properties and bioavailability, and is simple in structure and convenient for industrialization Production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117599063B_ABST
    Figure CN117599063B_ABST
Patent Text Reader

Abstract

The present invention discloses a use of a nucleoside compound in the preparation of poxvirus-related products. The nucleoside compound is a compound described in Formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. The nucleoside compound of the present invention can effectively prevent, alleviate or treat diseases caused by poxvirus infection or cytopathic effects caused by the replication or propagation of homologous variant viruses thereof. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmacy and relates to the use of a nucleoside compound in preparing poxvirus-related products and treating diseases caused by poxvirus infection. Background Art

[0002] Monkeypox virus (MPXV), variola virus or smallpox virus and vaccinia virus belong to the Poxviridae family. Poxvirus is a type of double-stranded DNA linear virus with the largest virus particles (McCollum, AM, et al., 2014). Monkeypox is a zoonotic infectious disease caused by monkeypox virus. The disease was first discovered in monkeys in Singapore in 1958, hence the name. The disease was not discovered in humans until 1970 (Cho, CT & Wenner, HA, 1973). Monkeypox mainly occurs in Africa, and humans and animals will develop local or systemic purulent skin lesions after infection.

[0003] There is currently no specific drug for MPXV worldwide. The effectiveness of current treatments developed for smallpox against monkeypox is based only on preclinical experiments. There are currently two drugs approved by the US FDA for the treatment of smallpox: tecovirimat and brincidofovir, which are used in MPXV clinical trials in many places. Another drug approved by the US FDA for the treatment of other viral infections, cidofovir, is also undergoing clinical trials on MPXV.

[0004] Currently, monkeypox virus has attracted global attention. There is no effective anti-monkeypox virus drug on the market worldwide, and there is a severe drug shortage. With the increasing number of monkeypox cases around the world, it is particularly important to find effective anti-monkeypox virus drugs.

[0005] During the research on anti-new coronavirus drugs, the applicant's R&D team discovered that the previously studied nucleoside compound (CN113735862A) not only has anti-new coronavirus efficacy, but also shows an inhibitory effect on poxvirus. At present, there is no drug available for monkeypox virus infection, so this discovery will be of great significance to clinical research. Summary of the invention

[0006] The object of the present invention is to provide a use of a nucleoside compound in the preparation of a poxvirus-related product, wherein the nucleoside compound is a compound described in Formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof. The nucleoside compound of the present invention can effectively prevent, alleviate or treat diseases caused by poxvirus infection or cytopathic effects caused by the replication or propagation of homologous variant viruses thereof.

[0007] In a first aspect, the present invention provides a use of a nucleoside compound in the preparation of a poxvirus-related product, wherein the nucleoside compound is a compound of formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof,

[0008]

[0009] in:

[0010] R 1 is selected from H, D, a fluorine atom or a chlorine atom;

[0011] R 2 , R 3 , R 4 , R 5 are each independently selected from H, D, a halogen atom, R 6 , R 7 ,OH,-OR 6 、-OR 7 、-NH 2 、-NHR 6 、-NHR 7 、-NR 7 R 8 ,SH,-SR 7 、-SSR 7 , SeR 7 , L-type amino acid ester or D-type amino acid ester;

[0012] R 6 are independently selected from -C(=O)R 7 、-C(=O)OR 7 ,-C(=O)NHR 7 、-C(=O)NR 7 R 8 、-CH 2 OC(=O)OR 7 、-CH 2 OC(=O)NHR 7 、-CH 2 OC(=O)NR 7 R 8、-C(=O)SR 7 、-C(=S)R 7 、-S(=O)R 7 or -S(=O) 2 R 7 ;

[0013] R 7 and R 8 Selected from substituted or unsubstituted C 1 -C 10 Alkyl, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 3 -C 10 Cycloalkynyl, substituted or unsubstituted C 2 -C 10 Alkenyl, substituted or unsubstituted C 2 -C 10 Alkynyl, substituted or unsubstituted C 6 -C 20 Aryl, substituted or unsubstituted C 3 -C 20 Heterocyclic, substituted or unsubstituted C 6 -C 20 Aralkyl;

[0014] R 9 Selected from H or F;

[0015] and containing unnatural proportions of atomic isotopes at one or more atoms that constitute the compounds of Formula I.

[0016] The substituted or unsubstituted C 1 -C 10 The alkyl group may be selected from substituted or unsubstituted C 1 -C 5 Alkyl, substituted or unsubstituted C 2 -C 4 Alkyl, substituted or unsubstituted C 2 -C 3 alkyl.

[0017] The substituted or unsubstituted C 3 -C 10 The cycloalkyl group may be selected from substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted C 4 -C 10 Cycloalkyl, substituted or unsubstituted C 4 -C 8Cycloalkyl, substituted or unsubstituted C 4 -C 6 Cycloalkyl, substituted or unsubstituted C 5 -C 6 Cycloalkyl.

[0018] The substituted or unsubstituted C 3 -C 10 The cycloalkenyl group may be selected from substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 4 -C 10 Cycloalkenyl, substituted or unsubstituted C 4 -C 8 Cycloalkenyl, substituted or unsubstituted C 4 -C 6 Cycloalkenyl, substituted or unsubstituted C 5 -C 6 Cycloalkenyl.

[0019] The substituted or unsubstituted C 3 -C 10 The cycloalkynyl group may be selected from substituted or unsubstituted C 3 -C 10 Cycloalkynyl, substituted or unsubstituted C 4 -C 10 Cycloalkynyl, substituted or unsubstituted C 4 -C 8 Cycloalkynyl, substituted or unsubstituted C 4 -C 6 Cycloalkynyl, substituted or unsubstituted C 5 -C 6 Cycloalkynyl.

[0020] The substituted or unsubstituted C 2 -C 10 The alkenyl group may be selected from substituted or unsubstituted C 3 -C 10 Alkenyl, substituted or unsubstituted C 4 -C 10 Alkenyl, substituted or unsubstituted C 4 -C 8 Alkenyl, substituted or unsubstituted C 4 -C 6 Alkenyl, substituted or unsubstituted C 5 -C 6 Alkenyl.

[0021] The substituted or unsubstituted C 2 -C 10 The alkynyl group may be selected from substituted or unsubstituted C 3 -C10 Alkynyl, substituted or unsubstituted C 4 -C 10 Alkynyl, substituted or unsubstituted C 4 -C 8 Alkynyl, substituted or unsubstituted C 4 -C 6 Alkynyl, substituted or unsubstituted C 5 -C 6 Alkynyl.

[0022] The substituted or unsubstituted C 6 -C 20 The aryl group may be selected from substituted or unsubstituted C 6 -C 12 Aryl, substituted or unsubstituted C 6 -C 10 Aryl.

[0023] The substituted or unsubstituted C 3 -C 20 The heterocyclic group may be selected from substituted or unsubstituted C 4 -C 10 Heterocyclic, substituted or unsubstituted C 4 -C 6 Heterocyclic, substituted or unsubstituted C 4 -C 5 Heterocyclic group.

[0024] The substituted or unsubstituted C 3 -C 20 The hetero atom in the heterocyclic group may be a nitrogen atom or an oxygen atom.

[0025] The substituted or unsubstituted C 3 -C 20 The number of heteroatoms in the heterocyclic group may be 1 or 2.

[0026] The substitution of the present invention may include methyl, ethyl, propyl, isopropyl, phenyl, indolyl, pyrrole, amino, halogen atom, hydroxyl, hydroxymethyl, sulfhydryl, mercaptomethyl, cyano, cyanooxy, azide or C 16 Alkoxy substitution.

[0027] In some embodiments, the R 2 H, OH or -R 6 .

[0028] In some embodiments, the R 2 For H.

[0029] In some embodiments, the R 2 For OH.

[0030] In some embodiments, the R 2 For-R 6 .

[0031] In some embodiments, the R 9 It is H or F.

[0032] In some embodiments, the R 9 For H.

[0033] In some embodiments, the R 9 For F.

[0034] In some embodiments, the R 3 and R 4 For OH.

[0035] In some embodiments, the R 1 H, F or D.

[0036] In some embodiments, the R 1 For H.

[0037] In some embodiments, the R 1 For F.

[0038] In some embodiments, the R 1 is D.

[0039] In some embodiments, the R 5 For-OR 6 , L-type amino acid ester or D-type amino acid ester.

[0040] In some embodiments, the R 5 For-OR 6 .

[0041] In some embodiments, the R 2 H, OH or -R 6 ; R 9 H or F; R 3 and R 4 OH; R 1 H, F or D; R 5 For-OR 6 , L-amino acid ester or D-amino acid ester; R 6 -C(=O)R 7 .

[0042] In some embodiments, the compound represented by formula I is a compound represented by formula II:

[0043]

[0044] In some embodiments, the R 7 Selected from phenyl, 2-propyl, methyl, ethyl, -CH 2 CF 3 , 1-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, octyl, naphthyl, tetrahydro-2H-pyranyl and 1-methylpiperidinyl.

[0045] In some embodiments, the R 7 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0046] In some embodiments, the compound represented by Formula I comprises any one selected from the following structures:

[0047]

[0048]

[0049]

[0050]

[0051]

[0052] In some embodiments, the nucleoside compound may also be selected from the nucleoside compound of formula (I) disclosed in CN113185519A, wherein R 1 The definition of is as described in its specification and will not be repeated here.

[0053]

[0054] Nucleoside compounds of the present invention can comprise atomic isotopes of non-natural ratios on one or more atoms constituting the compound. For example, radioactive isotope labeled compounds can be used, such as tritium (3H), iodine-125 (125I) or C-14 (14C). The conversion of all isotopic compositions of compounds of the present invention, whether radioactive or not, is included within the scope of the present invention.

[0055] In some more preferred embodiments, the compound represented by formula I comprises any one selected from the following structures:

[0056]

[0057] In some embodiments, the compound represented by Formula I does not include the following structure:

[0058]

[0059] In some embodiments, the nucleoside compound is independently selected from the following compounds, their stereoisomers, their tautomers, their crystalline hydrates, their solvates, their prodrugs or their pharmaceutically acceptable salts:

[0060]

[0061] The poxviruses described in the present invention include the subfamily Chordopoxvirinae and the subfamily Entomopoxvirinae.

[0062] In the present invention, the subfamily of vertebrate poxvirus includes Orthopoxvirus, Parapoxvirus, Avipoxvirus, Suipoxvirus, Capripoxvirus, Cervidopoxvirus, Leporipoxvirus, Molluscipoxvirus and Yatapoxvirus.

[0063] In the present invention, the orthopoxvirus genus includes Variola virus, Vaccinia virus, Ectromelia virus, Monkey pox virus, Rabbit pox virus, Buffalo pox virus, Cow pox virus, Camel pox virus and Horse pox virus.

[0064] In the present invention, the poxvirus-related product can be used to prevent, alleviate or treat diseases caused by poxvirus infection or cytopathic effects caused by the replication or propagation of poxvirus homologous variant viruses.

[0065] In the present invention, the infection is caused by poxvirus and includes at least one of skin lesions, fever, headache, fatigue, muscle aches, superficial lymphadenopathy, coma, edema and multiple organ failure.

[0066] In a second aspect, the present invention provides a method for preventing, alleviating or treating diseases caused by poxvirus infection or cytopathic effects caused by the replication or propagation of homologous variant viruses thereof by administering the above-mentioned nucleoside compounds to patients.

[0067] In a third aspect, the present invention provides the use of the above-mentioned nucleoside compounds in the preparation of products for detecting poxviruses or homologous variant viruses thereof.

[0068] In the present invention, the product for detecting poxvirus or its homologous variant virus includes reagents and kits.

[0069] In a fourth aspect, the present invention provides the use of the above-mentioned nucleoside compounds in detecting poxviruses or homologous variant viruses thereof.

[0070] In a fifth aspect, the present invention provides a use of a pharmaceutical composition in the preparation of poxvirus-related products, wherein the pharmaceutical composition comprises the above-mentioned nucleoside compound and a pharmaceutically acceptable excipient.

[0071] In the present invention, the pharmaceutical composition can be in the form of tablets, pills, creams, emulsions, ointments, suspensions, lyophilized preparations, capsules, sustained-release preparations, granules, granules, injections or sprays.

[0072] In the present invention, the pharmaceutical composition may also include Chinese medicine ingredients and / or Western medicine ingredients.

[0073] In the present invention, the poxvirus-related product is suitable for humans or animals.

[0074] In the present invention, the animals include bovines, equines, ovines, porcines, canines, felines, lagomorphs, birds, rodents or primates.

[0075] In a sixth aspect, the present invention provides a method for preventing, alleviating or treating diseases caused by poxvirus infection or cytopathic effects caused by the replication or propagation of its homologous variant viruses by administering the above-mentioned pharmaceutical composition to patients.

[0076] In a seventh aspect, the present invention provides the use of the above-mentioned pharmaceutical composition in the preparation of a product for detecting poxvirus or its homologous variant virus.

[0077] In an eighth aspect, the present invention provides use of the above-mentioned pharmaceutical composition in detecting poxvirus or its homologous variant virus.

[0078] Beneficial effects of the present invention

[0079] (1) The results of vaccinia virus cell experiments have shown that the nucleoside compounds of the present invention show better activity (more than 900 times) than existing drugs for treating smallpox.

[0080] (2) Monkeypox virus cell experiments have shown that the nucleoside compounds of the present invention have 10 to 26 times better activity than cidofovir and remdesivir.

[0081] (3) The nucleoside compounds of the present invention have good pharmacokinetic properties and higher bioavailability, among which the bioavailability of compound ATV014 is as high as 49%.

[0082] (4) The nucleoside compounds of the present invention have simple structures and simple synthesis processes, which are conducive to industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1 The drug-time curve of compound ATV014 on rat physical strength, wherein the horizontal axis is time in hours, and the vertical axis is plasma concentration in ug / L.

[0084] Figure 2 It is the inhibitory effect of different compounds on vaccinia virus, wherein the horizontal axis is the compound and the vertical axis is the relative DNA replication level of the virus.

[0085] Figure 3 The graphs show the inhibition curves and cell survival curves of different compounds on vaccinia virus, wherein the horizontal axis represents the drug concentration, the left vertical axis represents the inhibition rate (circles), and the right vertical axis represents the cell survival rate (triangles).

[0086] Figure 4 The antiviral activity of different compounds against monkeypox virus, wherein the horizontal axis represents the compound and the vertical axis represents the relative DNA replication level of the virus.

[0087] Figure 5 This is a graph showing the inhibition of monkeypox virus by different compounds, wherein the horizontal axis represents the drug concentration and the vertical axis represents the inhibition rate. DETAILED DESCRIPTION

[0088] Definition of terms

[0089] Unless otherwise indicated, the following terms and phrases as used herein have the following meanings:

[0090] Vaccinia virus: Vaccinia virus stored in a BSL-2 laboratory.

[0091] Monkeypox virus: Monkeypox virus stored and isolated in a BSL-3 laboratory.

[0092] In the present invention, expressions such as "compound I" and "compound represented by formula I" refer to the same compound. In the present invention, "composition" and "preparation" can be used interchangeably.

[0093] The "H" is a hydrogen atom, the "D" is a deuterium atom, and the "halogen atom" is a fluorine atom (F), a chlorine atom (Cl), a bromine atom (Br), an iodine atom (I), an astatine atom (At), or a thiophene atom (Ts).

[0094] In the present invention, "room temperature" refers to ambient temperature, which is from about 10 to about 40°C. In some embodiments, "room temperature" refers to a temperature from about 20 to about 30°C; in other embodiments, "room temperature" refers to a temperature from about 25 to about 30°C; in still other embodiments, "room temperature" refers to 10, 15, 20, 25, 30, 35, 40°C, etc.

[0095] "Alkyl" is a hydrocarbon containing positive, secondary, tertiary, or cyclic carbon atoms. For example, an alkyl group can have 1 to 10 carbon atoms (i.e., C 1 -C 10 alkyl), 1 to 8 carbon atoms (i.e., C 1 -C 8 alkyl) or 1 to 6 carbon atoms (i.e., C 1 -C 6 Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (i-Pr, i-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH (CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH (CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl-2-butyl (-C(CH 3 ) 2 CH 2 CH 3 )、3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-1-butyl (-CH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butyl (-CH 2 CH(CH 3 )CH 2 CH 3 )、1-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH 2 CH 3 )、3-hexyl(-CH(CH 2 CH 3 )(CH 2 CH 2 CH 3 ))、2-methyl-2-pentyl (-C(CH 3 ) 2 CH 2 CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2), 3-methyl-3-pentyl (-C(CH 3 )(CH 2 CH 3 ) 2 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH 3 ) 2 ), 2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH(CH 3 ) 2 ), 3,3-dimethyl-2-butyl (-CH(CH 3 )C(CH 3 ) 3 and octyl (-(CH 2 ) 7 CH 3 ).

[0096] An "alkenyl group" is a group containing at least one unsaturated site, i.e., a carbon-carbon sp 2 For example, an alkenyl group can have 2 to 10 carbon atoms (C 2 -C 10 alkenyl), 2 to 12 carbon atoms (C 2 -C 12 alkenyl) or 2 to 6 carbon atoms (C 2 -C 6 Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (—CH═CH 2 ), allyl (-CH 2 CH=CH 2 ), cyclopentenyl (-C 5 H 7 ) and 5-hexenyl (-CH 2 CH 2 CH 2 CH 2 CH=CH 2 ).

[0097] "Alkynyl" is a hydrocarbon containing a positive, secondary, tertiary, or cyclic carbon atom with at least one unsaturated site, i.e., a carbon-carbon sp triple bond. For example, an alkynyl group can have 2 to 10 carbon atoms (C 2 -C 10 Alkynyl), 2 to 12 carbon atoms (C 2 -C 12 Alkynyl) or 2 to 6 carbon atoms (C 2 -C 6Examples of suitable alkynyl groups include, but are not limited to, ethynyl (—C═CH), propargyl (—CH 2 C═CH) and the like.

[0098] "Cycloalkyl" is a non-aromatic cyclic hydrocarbon with a specific number of carbon atoms, including cyclized alkyl, alkenyl and alkynyl. Cycloalkyl can include monocyclic groups or polycyclic (e.g., rings with 2, 3 or 4 fused or bridged) groups. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarbyl, adamantyl, etc. In the definition of cycloalkyl, groups with one or more aromatic rings fused to the cycloalkyl ring (i.e., having a common key with the cycloalkyl ring) are also included, such as benzo derivatives of cyclopentane (i.e., indanyl), benzo derivatives of cyclopentene, benzo derivatives of cyclohexane, etc. The term "cycloalkyl" also includes saturated cyclic groups with a specific number of carbon atoms. These cyclic groups can include fused or bridged polycyclic systems. Preferred cycloalkyl groups have 3 to 10 carbon atoms in their ring structure, more preferably 3, 4, 5 and 6 carbons in the ring structure. For example, "C3-C6 cycloalkyl" means groups such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0099] "Cycloalkenyl" refers to a ring-containing hydrocarbon group having at least one carbon-carbon double bond in the ring and having from 3 to 10 carbon atoms.

[0100] "Cycloalkynyl" refers to a ring-containing hydrocarbon group having at least one carbon-carbon triple bond in the ring and having from 3 to 10 carbon atoms.

[0101] "Aryl" means an aromatic hydrocarbon group derived by removing a hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms. Typical aryl groups include, but are not limited to, groups derived from benzene (e.g., phenyl), substituted benzenes, naphthalene, anthracene, biphenyl, and the like, and the like.

[0102] "Arylalkyl" refers to a radical in which the 3 The term "arylalkyl" refers to an alkyl radical having a carbon atom (carbon atom) and a cycloalkyl radical having a carbon atom (carbon atom). The term "arylalkyl" refers to an alkyl radical having a carbon atom (carbon atom) and a cycloalkyl radical having a carbon atom (carbon atom). Typical arylalkyl includes, but is not limited to, benzyl, 2-phenyl second-1-yl, naphthylmethyl, 2-naphthyl second-1-yl, naphthobenzyl, 2-naphthophenyl second-1-yl and analogue. Arylalkyl can comprise 7 to 20 carbon atoms, for example, alkyl moiety is 1 to 6 carbon atom, and aryl moiety is 6 to 14 carbon atoms.

[0103] The term "substituted" refers to alkyl, aryl, arylalkyl, heterocyclyl, heteroaryl, carbocyclyl, etc., for example, "substituted C 1 -C10 Alkyl", "substituted C 6 -C 20 Aryl", "substituted arylalkyl", "substituted C 1 -C 20 "Heterocycle" and "substituted carbocyclyl" refer to a C 1 -C 10 Alkyl, C 6 -C 20 Aryl, arylalkyl, C 1 -C 20 Heterocycle, carbocyclyl. Unless otherwise indicated, when the term "substituted" is used in conjunction with a group having two or more moieties capable of substitution, such as arylalkyl, the substituents may be attached to the aryl portion, the alkyl portion, or both.

[0104] As used herein, the term "prodrug" refers to any compound that, when administered to a biological system, produces a drug, i.e., an active ingredient, due to a spontaneous chemical reaction, an enzyme-catalyzed chemical reaction, photolysis, and / or a metabolic chemical reaction. A prodrug is thus a covalently modified analog or latent form of a therapeutically active compound.

[0105] As used herein, "heterocycle" or "heterocyclyl" includes, by way of example and without limitation, those heterocycles described in Paquette, Leo A.: Principles of Modern Heterocyclic Chemistry (WA Benjamin, New York, 1968), in particular Chapters 1, 3, 4, 6, 7 and 9: The Chemistry of Heterocyclic Compounds, A Series of Monographs^ (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19 and 28 and J. Am. Chem. Soc. (1960) 82:5566. In a particular embodiment of the invention, "heterocycle" includes "carbocycles" as defined herein, in which one or more (e.g. 1, 2, 3 or 4) carbon atoms have been replaced by heteroatoms (e.g. O, N or S). The term "heterocycle" or "heterocyclyl" includes saturated rings, partially unsaturated rings and aromatic rings (i.e. heteroaromatic rings). Substituted heterocyclyl groups include, for example, heterocycles substituted with any of the substituents disclosed herein including carbonyl.

[0106] Examples of heterocycles include, by way of example and not limitation, pyridinyl, dihydropyridinyl, tetrahydropyridinyl (piperidinyl), thiazolyl, tetrahydrothienyl, thiooxytetrahydrothienyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthyl, indolyl, indolene, quinolyl, isoquinolyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidinonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, octahydroisoquinolyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenolic flavinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl pyridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatoacyl, and bis-tetrahydrofuranyl.

[0107] "Heteroaryl" refers to an aromatic heterocyclic radical having at least one heteroatom in the ring. Non-limiting examples of suitable heteroatoms that may be included on the aromatic ring include oxygen, sulfur and nitrogen. Non-limiting examples of heteroaryl rings include all those aromatic rings listed in the definition of "heterocyclic radical", including pyridyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furyl, thienyl, benzofuranyl, benzothienyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazolyl etc.

[0108] "Prodrug moiety" refers to an unstable functional group that is separated from an active inhibitory compound during metabolism, systemically, intracellularly, by hydrolysis, enzymatic cleavage, or by some other process (Bundgaard, Hans, "Design and Application of Prodrugs" in Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, 113-191 pages). Prodrug moieties can be used to enhance solubility, absorption, and lipophilicity to optimize drug delivery, bioavailability, and efficacy.

[0109] The prodrug moiety may include an active metabolite or the drug itself.

[0110] The compound shown in Formula I or its pharmaceutically acceptable salt can exist as different polymorphs or pseudopolymorphs. Crystal polymorphism used herein refers to the ability of a crystalline compound to exist in different crystal structures. Crystal polymorphism can be derived from differences in crystal packing (stacking polymorphism) or packing differences between different conformers of the same molecule (conformational polymorphism). Crystal pseudopolymorphism used herein refers to the ability of a hydrate or solvate of a compound to exist in different crystal structures. The pseudopolymorphs of the present invention can exist due to differences in crystal packing (stacking pseudopolymorphism) or due to packing differences between different conformers of the same molecule (conformational pseudopolymorphism). The present invention includes all polymorphs and pseudopolymorphs of Formula I-III compounds and their pharmaceutically acceptable salts.

[0111] The compound shown in formula I or its pharmaceutically acceptable salt can also exist as an amorphous solid. Amorphous solids used herein are such solids, wherein there is no long-range order in the positions of the atoms in the solid. This definition also applies when the crystal size is 2 nanometers or less. Additives including solvents can be used to establish the amorphous form of the present invention. The present invention includes all amorphous forms of compounds of formula I-III and their pharmaceutically acceptable salts.

[0112] The term "treat", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progression of, or preventing the condition or disorder, or one or more symptoms of such condition or disorder, to which the term applies. The term "treat", as used herein, refers to the act of treating, as "treating" is defined immediately above.

[0113] An "effective amount" of a compound as described herein refers to an amount sufficient to elicit a desired biological response. The effective amount of a compound as described herein may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, an effective amount is a therapeutically effective amount. Alternatively, in a separate method or use, the present invention may be used as a preventive treatment where indicated and effective. In certain embodiments, an effective amount is the amount of a compound as described herein in a single dose. In certain embodiments, an effective amount is the combined amount of a compound as described herein in multiple doses.

[0114] The "therapeutically effective amount" of the nucleoside compounds described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disease or sufficient to delay or minimize one or more symptoms associated with the disease. The therapeutically effective amount of a nucleoside compound means the amount of a therapeutic agent that provides a therapeutic benefit in the treatment of a disease alone or in combination with other therapies. The term "therapeutically effective amount" may encompass an amount that improves overall therapy, reduces or avoids symptoms, signs or causes of disease and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient to treat any disease or disease described.

[0115] The compounds I described herein also include reference to their physiologically acceptable salts, examples of which include salts derived from appropriate bases, such as alkali metals or alkaline earth metals (e.g., Na + , Li + , K + , Ca +2 and Mg +2 ), ammonium and NR 4 + (wherein R is as defined herein). Physiologically acceptable salts of nitrogen atoms or amino groups include: (a) acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; (b) salts formed with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalene, and the like. (c) salts with elemental anions, such as chlorine, bromine and iodine. Physiologically acceptable salts of hydroxy compounds include salts of the anions of the compounds with hydroxy groups, such as sodium + and NR4 + A combination of appropriate cations.

[0116] For therapeutic use, the salts of the active ingredients of the compounds I of the present invention are physiologically acceptable, i.e., they are salts derived from physiologically acceptable acids or bases. However, salts that are not physiologically acceptable acids or bases can also be used, for example, to prepare or purify physiologically acceptable compounds. All salts, whether or not derived from physiologically acceptable acids or bases, are within the scope of the present invention.

[0117] The compounds described in formula I may have chiral centers, such as chiral carbons. The compounds described in formula I therefore include racemic mixtures of all stereoisomers, including enantiomers, diastereomers and atropisomers. In addition, the compounds described in the present invention include optical isomers enriched or separated at any or all asymmetric chiral atoms. In other words, chiral centers similar to the description are provided in the form of chiral isomers or racemic mixtures. Racemic and diastereomeric mixtures, as well as separate or synthesized, substantially free of their enantiomers or diastereomeric partners, are within the scope of the present invention. Racemic mixtures are separated into their separate, substantially optically pure isomers by known techniques, such as separation of diastereomeric salts formed with optically active auxiliary agents (such as acids or bases), which are then converted back to optically active substances. In most cases, starting from the appropriate stereoisomers of the desired raw materials, the desired optical isomers are synthesized by stereospecific reactions.

[0118] Whenever Compound I described herein is represented by more than one identical designated group (e.g., "R" or "R 1 ”), it is to be understood that these groups may be the same or different, i.e., each group is independently selected.

[0119] Anti-acne virus activity detection method

[0120] Another aspect of the present invention relates to a method for detecting anti-poxvirus activity, comprising the step of treating a sample suspected of containing poxviruses with the nucleoside compound of the present invention.

[0121] The nucleoside compounds of the present invention can be used as anti-pox virus compounds, as intermediates of such nucleoside compounds, or have other uses as described below. The nucleoside compounds will bind to a position on a surface or in a cavity having a geometry unique to poxviruses. Compounds that bind to anti-poxviruses can bind to different degrees of reversibility. Those compounds that are essentially irreversibly bound are ideal candidates for this method of the present invention. Once labeled, those compositions that are essentially irreversibly bound can be used as probes for detecting poxviruses. Therefore, the present invention relates to a method for detecting poxviruses in a sample suspected of containing poxviruses, comprising the following steps: treating a sample suspected of containing poxviruses with a composition comprising a compound of the present invention bound to a marker; and observing the effect of the sample on the activity of the marker. Suitable markers are well known in the field of diagnostics and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups, and chromogens. The compounds herein are labeled in a conventional manner using functional groups (e.g., hydroxyl, carboxyl, sulfhydryl, or amino).

[0122] In the context of the present invention, samples suspected of containing poxviruses include natural or artificial materials, such as living organisms; tissue or cell cultures; biological samples, such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, etc.); laboratory samples; food, water or air samples; biological product samples, such as cell extracts, especially recombinant cell extracts that synthesize the desired glycoprotein, etc. Typically, the sample will be suspected of containing organisms that produce poxviruses, often pathogenic organisms, such as Poxviridae. The sample can be contained in any medium, including water and organic solvent / water mixtures. The sample includes living organisms, such as humans and artificial materials, such as cell cultures.

[0123] The treatment step of the present invention comprises adding the nucleoside compound of the present invention to the sample, or it comprises adding a precursor of the nucleoside compound to the sample. The adding step comprises any of the administration methods described above.

[0124] If necessary, the activity of poxvirus after administration of the compounds or compositions provided by the present invention can be observed by any method, including direct and indirect methods for detecting in vivo or in vitro anti-poxvirus activity. Quantitative, qualitative and semi-quantitative methods for detecting poxvirus activity are all conceived. Typically, one of the above-mentioned screening methods is applied, however, any other method may also be applied, such as observing the physiological properties of living organisms, etc. Poxvirus experiments have shown that, in the present invention, the following compounds, their stereoisomers, their tautomers, their crystalline hydrates, their solvates, their prodrugs or their pharmaceutically acceptable salts have good biological activity.

[0125]

[0126] Screening of active compositions against poxvirus

[0127] The nucleoside compounds of the present invention are suitable for treating or preventing poxviridae infections in animals or humans. However, in the screening of compounds capable of inhibiting poxviridae viruses, cell-based and animal (rodent) assays are the main screening tools.

[0128] Screening of the compositions of the invention for compounds having anti-pox virus activity may be performed by any conventional technique for evaluating antiviral activity. In the context of the present invention, typically, compositions having anti-pox virus activity are first screened, and then compositions exhibiting antiviral activity are screened for in vivo activity. -6 M and preferably less than about 1×10 -7 Compositions with in vitro Ki (inhibition constant) values ​​of M are preferably used in vivo. Useful in vitro screens have been described in detail in the literature and will not be described in detail here. However, the Examples describe suitable in vitro assays.

[0129] Pharmaceutical compositions, reagents, and kits

[0130] The pharmaceutical composition described in the present invention comprises a nucleoside compound, a stereoisomer, a tautomer, a crystalline hydrate, a solvate, a prodrug or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient described in Formula I. In certain embodiments, the nucleoside compound, a stereoisomer, a tautomer, a crystalline hydrate, a solvate, a prodrug or a pharmaceutically acceptable salt thereof described herein is provided in a pharmaceutical composition in an effective amount (e.g., a therapeutically effective amount).

[0131] The pharmaceutical compounds of the present invention are formulated with conventional carriers and excipients, which will be selected in accordance with conventional practice. Although the active ingredients can be administered alone, they are preferably formulated into pharmaceutical preparations. The preparations of the present invention, whether for veterinary or human use, contain at least one active ingredient as defined above and one or more acceptable carriers therefor, and optionally contain other therapeutic ingredients, especially those additional therapeutic ingredients as disclosed herein. The carrier must be "acceptable" in the sense that it is compatible with the other components of the formulation and is physiologically harmless to its recipient.

[0132] The pharmaceutical compositions described herein can be prepared by any method known in pharmacy. Generally speaking, these preparation methods include associating the nucleoside compound (i.e., "active ingredient") with a carrier or excipient and / or one or more other auxiliary ingredients, and then if necessary and / or desired, the product is molded and / or packaged into a desired single dose or multiple dose unit.

[0133] The pharmaceutical composition of the present invention can be prepared according to known methods, such as the methods described in the general rules for preparation of the 16th edition of the Japanese Pharmacopoeia, the United States Pharmacopoeia, and the 9th edition of the European Pharmacopoeia. The pharmaceutical composition of the present invention can be appropriately administered to patients depending on the dosage form.

[0134] Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. A "unit dose" is a discrete amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dose of the active ingredient administered to a subject and / or a convenient fraction of the dose (e.g., one-half or one-third of the dose).

[0135] The active ingredients, pharmaceutically acceptable excipients in the pharmaceutical compositions described herein will vary depending on the identity, size and / or condition of the subject being treated and further on the route of administration of the composition. The pharmaceutical composition may contain between 0.1% and 100% (w / w) active ingredients.

[0136] Pharmaceutically acceptable excipients used in the preparation of the provided pharmaceutical compositions include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients (e.g., cocoa butter and suppository wax), colorants, coating agents, sweeteners, flavoring agents, and aromatics may also be present in the pharmaceutical compositions.

[0137] The invention further provides veterinary compositions comprising at least one active ingredient as defined above together with a veterinary carrier therefor.

[0138] Veterinary carriers are substances useful for the purpose of the veterinary composition and may be solid, liquid or gaseous substances which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.

[0139] Route of administration

[0140] One or more compounds of the present invention (referred to herein as active ingredients) are administered by any route suitable for the condition being treated. Suitable routes include oral, rectal, nasal, pulmonary, topical (including oral and sublingual) and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), etc. It should be understood that the preferred route may vary with, for example, the condition of the recipient. The benefits of the compounds of the present invention are that they are orally bioavailable and can be administered orally.

[0141] Metabolites of the compounds of the present invention

[0142] Also within the scope of the invention are the in vivo metabolic products of the compounds described herein, to the extent such products are novel and unobvious over the prior art. These products may result, for example, from oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compound, primarily due to enzymatic processes. Thus, the invention includes novel and unobvious compounds produced by a process comprising contacting a compound of the invention with a mammal for a period of time sufficient to produce a metabolic product thereof. Such products are typically identified by preparing a radiolabeled (e.g. 14 C or 3 H) of the present invention, administering it parenterally to an animal, such as a rat, mouse, guinea pig, monkey or human, at a detectable dose (e.g., greater than about 0.5 mg / kg), allowing sufficient time for metabolism to occur (typically, about 30 seconds to 30 hours), and separating its conversion products from urine, blood or other biological samples. Because they are labeled, these products are easily separated (others are separated using antibodies that can bind to epitopes remaining in the metabolites). The structure of the metabolites is determined in a conventional manner, such as by MS or NMR analysis. In general, the analysis of metabolites is carried out in the same manner as conventional drug metabolism studies known to those skilled in the art. Conversion products, provided that they are not otherwise found in vivo, can also be used for diagnostic assays for therapeutic administration of the compounds of the present invention, even if they do not themselves have novel coronavirus polymerase inhibitory activity.

[0143] Formulas and methods for determining the stability of compounds in surrogate gastrointestinal secretions are known. Compounds are defined herein as being stable in the gastrointestinal tract where less than about 50 mole percent of the protected groups are deprotected in a surrogate of intestinal or gastric fluids after incubation at 37°C for 1 hour. It cannot be assumed that compounds will not hydrolyze in vivo simply because they are stable to the gastrointestinal tract. The prodrugs of the present invention are typically stable in the digestive system, but they are generally substantially hydrolyzed to the parent drug in the digestive lumen, liver or other metabolic organs or within cells.

[0144] It should also be noted that the specific dosage and method of use of the compound having the structure of Formula I, its stereoisomers, its tautomers, its crystalline hydrates, its solvates, its prodrugs and its pharmaceutically acceptable salts for different patients are determined by many factors, including the patient's age, weight, sex, natural health, nutritional status, the activity strength of the drug, the time of administration, the metabolic rate, the severity of the disease and the subjective judgment of the treating physician. The effective dose of the active ingredient depends at least on the nature of the disease to be treated, the toxicity (whether the compound is used for prevention or against active viral infection), the method of delivery and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. It can be expected that the dosage is about 0.0001 to about 100 mg / kg body weight per day; typically, about 0.01 to about 10 mg / kg body weight per day; more typically, about 0.01 to about 5 mg / kg body weight per day; most typically, about 0.05 to about 0.5 mg / kg body weight per day. For example, for an adult human of about 70 kg, a candidate daily dosage would be in the range of 1 mg to 1000 mg, preferably 5 mg to 500 mg, and may be in the form of a single dose or multiple doses.

[0145] In describing the experimental details, certain abbreviations and acronyms are used. Although most of them are understood by those skilled in the art, the following Table 1 contains a list of these abbreviations and acronyms.

[0146] Table 1

[0147]

[0148]

[0149] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting embodiments are further disclosed below to further illustrate the present invention in detail.

[0150] The reagents used in the present invention can be purchased from the market or prepared by the method described in the present invention.

[0151] In the present invention, μM means micromole per liter; mmol means millimole; and equiv means equivalent.

[0152] Example 1 Synthesis of (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-2-cyano-5-(isobutyl formate)tetrahydrofuran-3,4-bis(2-isobutyl formate) (A3)

[0153]

[0154] Take 594 mg (2 mmol) of compound 1-1, 50 mg (0.4 mmol, 0.2 equiv) of 4-dimethylaminopyridine, 804 mg (1.2 mL, 11 mmol, 5.5 equiv) of EDMA (N,N-dimethylethylamine) and 1.58 g (1.66 mL, 10 mmol) of isobutyric anhydride, mix, mix the obtained mixture with 10 mL of acetonitrile, stir at 40 for 1 hour, remove the organic solvent by rotary evaporation, and the crude product is eluted by silica gel chromatography (methanol / dichloromethane (V / V) = 5 / 95) to obtain 410 mg of compound A3 (colorless viscous liquid, yield 35%). 1 H NMR (400 MHz, CDCl 3 )δ7.89(s,1H),6.86(d,J=4.7Hz,1H),6.70(d,J=4.7Hz,1H),6.28(d,J=5.9Hz,1H),5.53(dd,J=5.7,4 .4Hz,1H),4.65(q,J=4.1Hz,1H),4.42(qd,J=12.3,4.1Hz,2H),2.75-2.51(m,3H),1.32-1.10(m,18H). 13 C NMR (101 MHz, CDCl 3 )δ176.58,175.85,175.11,155.65,146.56,122.08,117.09,115.34,112.03,101.09,81.50, 77.04,71.99,70.63,62.66,33.85,33.82,33.74,18.96,18.82,18.78,18.69,18.67,18.54.

[0155] Example 2 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-isobutyric acid)methyl ester (A4)

[0156]

[0157] 5.62 g of compound 1-1 was dissolved in 30 mL of acetone, and then 11.50 mL of 2,2-dimethoxypropane and 1.34 mL of 98% sulfuric acid were added. The mixture was stirred at 45 °C for half an hour, cooled to room temperature, and the organic solvent was removed by rotary evaporation. The mixture was extracted with 100 mL of ethyl acetate and 100 mL of saturated sodium bicarbonate solution, and the extraction was repeated three times. The ethyl acetate layer was combined, dried with anhydrous sodium sulfate, and the sodium sulfate was removed by filtration. The organic solvent was removed by rotary evaporation, and 6.20 g of 4-1 (white solid, yield 97%) was obtained after column chromatography separation (petroleum ether / ethyl acetate (V / V) = 1 / 2). 1 H NMR(400MHz,Chloroform-d)δ7.95(s,1H),7.11(d,J=4.7Hz,1H),6.69(dd,J=4.8,2.4Hz,1H),5.77(s,2H),5.42(d,J=6.6Hz,1H),5.2 4(dd,J=6.6,2.4Hz,1H), 4.67(q,J=1.9Hz,1H), 3.99(dd,J=12.5,1.9Hz,1H), 3.84(dd,J=12.5,1.7Hz,1H), 1.81(s,3H), 1.40(s,3H).

[0158] 1.50 g of compound 4-1 was dissolved in 15 ml of dichloromethane, and then 0.42 mL of isobutyric acid and 55.40 mg of 4-dimethylaminopyridine were added. After stirring for 10 minutes, 1.02 g of dicyclohexylcarbodiimide was added and stirred at room temperature for 24 hours. After column chromatography separation (eluent: petroleum ether / ethyl acetate (V / V) = 1 / 1), 1.71 g of compound 4-2 (white solid, yield 94%) was obtained. 1 H NMR (400 MHz, CDCl 3 ,ZQF-RD01-2)δ(ppm):7.99(s,1H),6.99(d,J=4.6Hz,1H),6.62(d,J=4.6Hz,1H),5.72(br,2H),5.49(d,J=6.8Hz,1H),4.93-4.90(dd,J=6. 8Hz, 4.3Hz, 1H), 4.61-4.58 (q, J = 4.4Hz, 1H), 4.44-4.26 (m, 2H), 2.61-2.50 (m, 1H), 1.77 (s, 3H), 1.42 (s, 3H), 1.17-1.14 (q, J = 3.8Hz, 6H). 13 C NMR (100 MHz, CDCl 3,ZQF-RD01-2)δ(ppm):176.7,155.2,147.3,123.5,117.2,116.7,115.6,112.6,100.0,83.8,83.0,82.0,81.4,63.1,33.8,26.4,25.6,18.9.

[0159] 1.50 g of compound 4-2 was dissolved in 3 mL of 37% by mass aqueous hydrochloric acid solution and 15 mL of tetrahydrofuran. After stirring for 6 hours, sodium carbonate was added to adjust the pH to 8. The organic solvent was removed by rotary evaporation and separated by column chromatography (eluent: petroleum ether / ethyl acetate (V / V) = 1 / 3) to obtain 0.66 g of compound A4 (white solid, yield 49%). 1 H NMR (400 MHz, Methanol-d 4 )δ7.76(s,1H),6.78(s,2H),4.78(d,J=5.3Hz,1H),4.40-4.24(m,2H),4.24-4.1 1(m,1H),4.10-4.01(m,1H),2.42(p,J=7.0Hz,1H),0.99(dd,J=7.0,4.1Hz,6H). 13 C NMR (101MHz, Methanol-d 4 )δ176.96,155.82,146.92,124.25,116.54,116.29,110.75,101.20,82.04,80.00,74.27,70.68,62.93,33.58,25.00,17.95,17.87.

[0160] Example 3 Methyl ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)acetate (A5)

[0161]

[0162] According to the preparation method described in Example 2, acetic acid was used to replace the isobutyric acid in Example 2 to prepare compound A5, and 560 mg of white solid was obtained. The total yield of the latter two steps was 37.3%. 1 H NMR (600MHz, CD 3OD)δ(ppm):7.86(s,1H),6.89(t,J=5.0Hz,2H),4.87(s,1H),4.43-4.41(dd,J=12Hz, 2.8Hz,1H),4.37-4.34(m,1H),4.30-4.27(m,1H),4.13(t,J=5.7Hz,1H),2.03(s,3H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):171.0,155.8,146.9,124.2,116.6,116.2,110.7,101.1,81.9,80.2,74.1,70.7,63.1,19.3.

[0163] Example 4 Methyl ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)propanoate (A6)

[0164]

[0165] According to the preparation method described in Example 2, propionic acid was used instead of isobutyric acid in Example 2 to prepare compound A6 to obtain 500 mg of a white solid. The total yield of the latter two steps was 32%. 1 H NMR (600MHz, CD 3 OD)δ(ppm):7.86(s,1H),6.90-6.88(q,J=4.5Hz,2H),4.87-4.86(m,1H),4.46-4.43(dd,J=12Hz,2.8Hz,1 H), 4.37-4.36 (m, 1H), 4.31-4.28 (m, 1H), 4.15 (t, J = 5.8Hz, 1H), 2.38-2.28 (m, 2H), 1.08 (t, J = 7.5Hz, 3H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):174.3,155.8,146.9,124.2,116.5,116.2,110.7,101.1,82.0,80.1,74.2,70.7,62.9,26.7,7.9.

[0166] Example 5 Methyl ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)butanoate (A7)

[0167]

[0168] According to the preparation method described in Example 2, butyric acid was used instead of isobutyric acid in Example 2 to prepare compound A7 to obtain 600 mg of a white solid. The total yield of the latter two steps was 37%. 1 H NMR (600MHz, CD 3 OD)δ(ppm):7.86(s,1H),6.90-6.88(q,J=4.5Hz,2H),4.87-4.86(m,1H),4.44-4.42(dd,J=12Hz,2.8Hz,1H),4.37- 4.35(m,1H),4.31-4.28(m,1H),4.14(t,J=5.8Hz,1H),2.32-2.23(m,2H),1.62-1.56(m,2H),0.91(t,J=7.4Hz,3H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):174.3,155.9,146.9,124.3,116.5,116.2,110.7,101.1,82.0,80.1,74.2,70.7,62.8,35.4,17.9,12.5.

[0169] Example 6 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-cyclopropanecarboxylic acid methyl ester (A8)

[0170]

[0171] According to the preparation method described in Example 2, cyclopropylcarboxylic acid was used instead of isobutyric acid in Example 2 to prepare compound A8 to obtain 670 mg of a white solid. The total yield of the latter two steps was 41.8%. 1 H NMR (600MHz, CD 3 OD)δ(ppm):7.86(s,1H),6.89(t,J=4.5Hz,2H),4.87-4.86(m,1H),4.46-4.44(dd,J=12Hz,2.8Hz,1H ),4.36-4.34(m,1H),4.29-4.26(m,1H),4.15(t,J=5.8Hz,1H),1.64-1.60(m,1H),0.92-0.87(m,4H). 13 C NMR (150MHz, CD 3OD)δ(ppm):174.9,155.9,146.9,124.2,116.6,116.2,110.7,101.1,80.2,80.1,74.2,70.6,63.0,12.1,7.5,7.4.

[0172] Example 7 Methyl (((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)benzoate (A9)

[0173]

[0174] According to the preparation method described in Example 2, benzoic acid was used instead of isobutyric acid in Example 2 to prepare compound A9 to obtain 740 mg of a white solid. The total yield of the latter two steps was 41.5%. 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm):7.92(br,2H),7.90(d,J=7.4Hz,2H),7.86(s,1H),7.68(t,J=7.4Hz,1H), 7.52(t,J=7.7Hz,2H),6.87(d,J=4.5Hz,1H),6.81(d,J=4.5Hz,1H),6.36(d,J=5.9H z,1H),5.46(d,J=5.9Hz,1H),4.79(t,J=5.3Hz,1H),4.61-4.58(dd,J=12.2Hz,2.6H z,1H),4.45-4.42(dd,J=12.3Hz,4.8Hz,1H),4.39-4.37(m,1H),4.14-4.10(m,1H). 13 C NMR (150 MHz, DMSO-d 6 )δ(ppm):166.0,156.1,148.4,134.0,129.8,129.7,129.2,123.9,117.4,117.1,110.8,101.3,81.7,79.7,74.5,70.6,63.9.

[0175] Example 8 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-cyclohexanecarboxylic acid)methyl ester (A10)

[0176]

[0177] According to the preparation method described in Example 2, cyclohexylcarboxylic acid was used instead of isobutyric acid in Example 2 to prepare compound A10 to obtain 640 mg of a white solid. The total yield of the latter two steps was 35.5%. 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm):7.92(s,1H),7.86(br,1H),6.92(d,J=4.5Hz,1H),6.81(d,J=4.5Hz,1H),6.33 (d,J=5.9Hz,1H),5.38(d,J=5.9Hz,1H),4.70(t,J=5.3Hz,1H),4.32-4.29(dd,J=12.2Hz ,2.6Hz,1H),4.24-4.21(m,1H),4.16-4.13(dd,J=12.3Hz,4.8Hz,1H),3.98-3.95(q,J= 5.9Hz,1H),2.26-2.22(m,1H),1.75-1.72(m,2H),1.64-1.56(m,3H),1.30-1.12(m,5H). 13 CNMR (150MHz, DMSO-d 6 )δ(ppm):175.34,156.06,148.4,124.0,117.4,117.0,110.7,101.2,81.7,79.4,74.5,70.6,63.0,42.6,29.0,28.9,25.7,25.2,25.1.

[0178] Example 9 ((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl-5-d)-6-cyano-2,2-dimethyltetrahydrofuran[3,4-d][1,3]dioxol-4-yl)methylcyclohexanecarboxylate (A11)

[0179]

[0180] Compound 11-1 (0.5 g, 1.1 mmol) and N-iodosuccinimide (0.28 g, 1.2 mmol) were mixed with dichloromethane (10 mL), stirred at room temperature for 2 h, and then the solvent was removed under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether = 1 / 2 (V / V)) to give compound 11-2 (red solid, 400 mg, yield 64.1%).

[0181] Under argon conditions, a solution of D containing compound 11-2 (200 mg, 0.35 mmol) and cesium carbonate (247 mg, 0.76 mmol) was added. 2O-DMSO-d6 (10 mL, D 2 O:DMSO=1:9(V / V)) solution was added with PdCl 2 (dppf) 2 (32 mg, 0.04 mmol), 80 stirred for 10 hours, cooled to room temperature and slowly poured into water (10 mL), then extracted with ethyl acetate (30 mL × 2), combined the organic layers, washed with water and concentrated in vacuo to give a red oil, which was purified by column chromatography (eluent ethyl acetate / petroleum ether = 1 / 2 (V / V)) to give compound 11-3 (light red oil, 80 mg, yield 51.3%).

[0182] Compound 11-3 (80 mg, 0.18 mmol) was dissolved in a mixed solution of 6N hydrochloric acid aqueous solution (1 mL) and tetrahydrofuran (1.5 mL), stirred at 0-5 for 7 hours, and then heated with Na 2 CO 3 The pH was adjusted to 8, the solvent was removed in vacuo, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether=1 / 1 (V / V)) to obtain compound A11 (off-white solid, 45 mg, yield 62.1%). 1 H NMR (600 MHz, DMSO-d 6 )δ7.92(s,1H),7.86(br,1H),6.80(s,1H),4.69(d,J=4.8Hz,1H),4.30(dd,J=12.2,2.9Hz,1H),4.25-4.18(m,1H),4.14 (dd,J=12.2,4.9Hz,1H),3.99-3.90(m,1H),2.28-2.17(m,1H),1.79-1.68(m,2H),1.68-1.52(m,3H),1.34-1.07(m,5H).

[0183] Example 10 ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-cyclohexanecarboxylic acid)methyl ester (A12)

[0184]

[0185] Under nitrogen protection, 12-1 (25.2 g, 45.5 mmol) and dry DCM (55 mL) were added to a Schlenk tube, and trifluoromethanesulfonic acid TfOH (8.1 mL, 91.06 mmol) was added dropwise at 0. After the addition, the reaction solution was stirred for 10 minutes, and trimethylsilyl trifluoromethanesulfonate TMSOTf (16.5 mL, 95.6 mmol) was added dropwise. The reaction solution was stirred at 0°C for 30 minutes, and trimethylsilyl cyanide TMSCN (22.8 mL, 182.11 mmol) was added dropwise to the solution. After stirring at 0°C for 2 hours, the reaction was monitored by TLC. After the reaction was complete, triethylamine (22 mL) was slowly added dropwise to the solution, and the reaction solution was slowly warmed to room temperature. Sodium bicarbonate solution was added to the reaction solution and stirred, and extracted with DCM twice. The organic phases were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain light yellow oil 12-2 (10.13 g, 32.7% yield).

[0186] Add 12-2 (10 g, 17.80 mmol and anhydrous DCM (100 mL)) to a Schlenk tube. Cool the reaction solution to -78, add a DCM solution of boron trichloride (1M, 71.2 mL, 71.22 mmol) dropwise, and control the internal temperature to be below -45. After the addition is complete, warm the reaction solution to -40, stir for 2 hours, monitor the reaction by TLC, and the reaction is complete after the reaction is complete. Cool the solution to -78, add a mixed solution of methanol (20 mL) and triethylamine (30 mL) dropwise, and control the internal temperature to be below -40. After the addition is complete, warm the reaction solution to room temperature and concentrate. The crude product is subjected to column chromatography to obtain 12-3 (3.70 g, 69.7%) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 )δ8.94(s,1H),8.62(s,1H),8.12(s,1H),7.29(d,J=4.8Hz,1H),7.17(d,J=4.0Hz,1H),6.77(d,J=4.0Hz,1H),4.72(d,J=4.0Hz, 1H), 4.38 (dd, J=8.0Hz, 4.0Hz, 1H), 3.98-4.02 (m, 1H), 3.77 (dd, J=8.0Hz, 4.0Hz, 1H), 3.56 (q, J=8.0Hz, 1H). ESI-HRMS: m / z[M+H] + Calculate for C 19 H 24 N 5 O 5 :292.1046;found:292.1418.

[0187] According to the preparation method described in Example 2, 12-3 was used instead of 1-1, and cyclohexylcarboxylic acid was used instead of isobutyric acid in Example 2 to prepare compound A12 to obtain 0.45 g of off-white solid. The yield of the latter two steps was 25%. 1 H NMR (400 MHz, Methanol-d 4 )δ7.86(s,1H),6.91(d,J=4.6Hz,1H),6.80(d,J=4.6Hz,1H),5.01(d,J=4.2Hz,1H),4.71-4.55(m,2H),4.38-4.12(m,2 H),2.56-2.40(m,1H),2.08-1.93(m,2H),1.84-1.71(m,2H),1.70-1.61(m,1H),1.59-1.45(m,2H),1.41-1.27(m,3H).

[0188] Example 11 ((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl-5-d)-6-cyano-2,2-dimethyltetrahydrofuran[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate (A13)

[0189]

[0190] According to the preparation method of Example 9, compound 4-1 was substituted for 11-1 in Example to prepare compound A13, and 0.35 g of off-white solid was obtained. 1 H NMR (600 MHz, DMSO-d 6 )δ7.92(s,2H),7.87(br,1H),5.37(d,J=5.8Hz,1H),4.69(t,J=5.4Hz,1H),4.30(dd,J=12.1,2.8Hz,1H),4.26-4 .20(m,1H),4.17(dd,J=12.1,5.3Hz,1H),3.95(q,J=5.8Hz,1H),2.55-2.51(m,1H),1.05(dd,J=7.2,2.9Hz,6H).

[0191] Example 12 ((2R,3S,4R,5R)-5-(4-amino-5-fluoropyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl isobutyrate (A14)

[0192]

[0193] A4 (1 g, 2.77 mmol), Selectfluor (1-chloromethyl-4-fluoro-1,4-diazobicyclo 2.2.2 octane bis(tetrafluoroborate) salt, 1.4 g, 5.5 mmol) and DMAP (0.34 g, 2.77 mmol) were added to a mixed solvent of 20 ml of acetonitrile-water (v / v=9:1), and stirred at room temperature for 24 h. After TLC monitoring, the reaction of A4 was basically completed. The acetonitrile was removed by distillation under reduced pressure, and water and ethyl acetate were added. The organic layer was separated by stirring, and the aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, and the combined organic phases were washed with saturated sodium carbonate solution and saturated sodium chloride solution in turn, and then dried over anhydrous sodium sulfate, filtered and evaporated to dryness to obtain a dark red oil, which was separated and purified by column chromatography (DCM:MeOH=50:1) to obtain 100 mg of a nearly white solid with a yield of 9.5%. 1 H NMR (600MHz, CD 3 OD)δ(ppm):7.79(s,1H),6.65(s,1H),4.79(d,J=5.0Hz,1H),4.40-4.30(m,3H),4.09(t,J=5.6Hz,1H),2.59-2.54(m,1H),1.14-1.13(m,6H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):176.9,154.5,147.6,144.0,142.3,121.0,115.7,102.7,102.5,97.0,96.9,81.9,79.6,74.5,70.5,62.7,33.7,17.9,17.8. 19 F NMR (600MHz, CD 3 OD)δ(ppm):-160.8.

[0194] Example 13 (((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methylcyclopentanecarboxylate (A15)

[0195]

[0196] According to the preparation method described in Example 2, cyclopentanecarboxylic acid was used instead of isobutyric acid in Example 2 to prepare compound A15 to obtain 620 mg of a white solid. The total yield of the latter two steps was 35.6%. 1 H NMR (600MHz, CD 3OD)δ(ppm):7.86(s,1H),6.90-6.87(q,J=4.6Hz,2H),4.85-4.83(m,1H),4.39-4.43(dd,J=12.1Hz,3.1Hz ,1H),4.37-4.35(m,1H),4.14(t,J=5.7Hz,1H),2.75-2.70(m,1H),1.87-1.80(m,2H),1.75-1.53(m,6H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):176.5,155.9,146.9,124.3,116.5,116.2,110.7,101.1,82.0,80.0,74.3,70.7,62.8,43.5,29.5,29.4,25.3.

[0197] Example 14 (((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-3-methylbutyric acid-2-yl)methyl ester (A16)

[0198]

[0199] According to the preparation method described in Example 2, isovaleric acid was used instead of isobutyric acid in Example 2 to prepare compound A16 to obtain 750 mg of a white solid. The total yield of the latter two steps was 44.4%. 1 H NMR (600MHz, CD 3 OD)δ(ppm):7.86(s,1H),6.90-6.88(q,J=4.6Hz,2H),4.87(d,J=5.3Hz,1H),4.43-4.40(m,1H),4.39-4.35(m,2 H), 4.31-4.29 (m, 1H), 4.14 (t, J = 5.7Hz, 1H), 2.18-2.16 (m, 2H), 2.04-1.97 (m, 1H), 0.91-0.90 (q, J = 3.2Hz, 6H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):155.9,146.9,124.3,116.5,116.2,110.7,101.1,82.0,80.0,74.2,70.7,70.6,62.8,62.7,42.6,25.4,21.3,21.2.

[0200] Example 15 (((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-pivalic acid-2-yl ester (A17)

[0201]

[0202] According to the preparation method described in Example 2, pivalic acid was used instead of isobutyric acid in Example 2 to prepare compound A17 to obtain 360 mg of a white solid. The total yield of the latter two steps was 21.3%. 1 H NMR (600MHz, CD 3 OD)δ(ppm):7.86(s,1H),6.89-6.87(q,J=4.6Hz,2H),4.86(d,J=5.3Hz,1H) ,4.39-4.36(m,2H),4.32-4.29(m,1H),4.16(t,J=5.6Hz,1H),1.15(s,9H). 13 C NMR (150MHz, CD 3 OD)δ(ppm):155.9,146.9,124.3,116.6,116.2,110.7,101.1,82.0,79.9,74.2,70.6,63.0,38.5,26.1.

[0203] Example 16 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl D-valine ester (A18)

[0204]

[0205] 1.80 g of compound 4-1 was dissolved in 15 mL of acetonitrile, followed by the addition of 1.18 g of (D)-Boc-valine, 66.48 mg of 4-dimethylaminopyridine, and 1.2 g of DIC, and stirred at room temperature for 24 h. After column chromatography (petroleum ether / ethyl acetate (V / V) = 1 / 1), 2.81 g of compound 18-1 (white solid, yield 97%) was obtained. 1H NMR (600MHz, CD3OD) δ7.79(s,1H),6.79(s,2H),5.39(s,1H),4.90(dd,J=6.5,3.4Hz,1H),4.51(q,J=4.1Hz,1H),4.29(dd,J=12.0,3.8Hz,1H),4.2 4(dd,J=12.1,5.2Hz,1H),3.77(d,J=6.0Hz,1H),3.27-3.11(m,1H),1.61 (s, 4H), 1.32 (d, J = 2.5Hz, 9H), 1.24 (s, 3H), 0.73 (dd, J = 19.0, 6.8Hz, 6H). 13 C NMR (151 MHz, CD 3 OD)δ172.00,156.84,155.83,147.06,123.47,116.84,116.25,115.65 ,110.76,101.11,84.49,82.89,82.02,81.17,79.18,63.54,59.24,53 .42,48.04,47.91,47.90,47.84,47.76,47.62,47.56,47.48,47.33,4 7.19,33.37,30.06,27.32,25.35,25.14,24.66,24.14,18.14,16.90.

[0206] 2.50 g of compound 18-1 was dissolved in 3 mL of concentrated hydrochloric acid and 15 mL of tetrahydrofuran. After stirring for 6 hours, sodium carbonate was added to adjust the pH to 8. The organic solvent was removed by a rotary evaporator and separated by column chromatography (methanol / ethyl acetate (V / V) = 1:20) to obtain 0.99 g of compound A18 (white solid, yield 54%). 1 H NMR (400MHz, CD 3 OD)δ7.76(s,1H),6.80(s,2H),4.79(s,1H),4.42-4.24(m,3H),4.08(d,J=5.5Hz,1H),3 .23(d,J=11.1Hz,1H),1.90-1.76(m,1H),0.82(d,J=6.9Hz,3H),0.74(d,J=6.9Hz,3H).

[0207] Example 17 ((3aR,4R,6R,6aR)-6-(4-aminopyrrole[2,1-f][1,2,4]triazine-7-yl)-6-cyano-2,2-dimethyltetrahydrofuran[3,4-d][1,3]dioxolan-4-yl)methyl(tert-butylcarboester)-L-valine ester (A19)

[0208]

[0209] According to the method described in Example 16, N-Boc-D-valine was replaced with N-Boc-L-valine to synthesize compound A19 as a white solid (1.1 g). The total yield of the two steps was 60%. 1 H NMR (600MHz, CD 3 OD)δ7.76(s,1H),6.80(d,J=1.6Hz,2H),4.81(d,J=5.3Hz,1H),4.42-4.26(m,3H),4.04(t,J=5. 8Hz, 1H), 3.25 (d, J = 4.9Hz, 1H), 1.97-1.84 (m, 1H), 0.83 (d, J = 6.9Hz, 3H), 0.79 (d, J = 6.9Hz, 3H). 13 C NMR (151 MHz, CD 3 OD)δ173.76,155.85,146.93,124.12,116.62,116.21,110.86,101.11,81.75,80.16,74.04,70.76,63.66,59.27,31.62,17.75,16.46.

[0210] Example 18 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydrofuran-3-carboxylate (A20)

[0211]

[0212] 1.50 g of compound 4-1 was dissolved in 15 ml of dichloromethane, and then 0.63 g of tetrahydrofuran-3-carboxylic acid and 0.27 g of 4-dimethylaminopyridine were added. After stirring for 10 minutes, 1.1 g of dicyclohexylcarbodiimide was added and stirred at room temperature for 4 hours. After column chromatography separation (petroleum ether / ethyl acetate (V / V) = 1 / 1), 1.86 g of crude compound 3 was obtained (yield: 98%).

[0213] The crude product of compound 3 was dissolved in 10 mL (6.7 V) formic acid and 5 mL (3.3 V) water. After stirring at room temperature for 30 hours, the excess formic acid was evaporated, and the residue was dissolved in ethyl acetate. The pH was adjusted to 8 with saturated aqueous sodium carbonate solution, and the organic layer was separated. The aqueous layer was extracted twice with EA, and the organic layers were combined, washed with saturated brine, dried over sodium sulfate, filtered and evaporated. The crude product was separated by column chromatography (eluent: DCM / MeOH (V / V) = 10 / 1) to obtain 1.2 g of compound A20 (white solid, two-step yield was 69%). 1 H NMR (600 MHz, DMSO-d 6 )δ7.94(s,1H),7.90(br,2H),6.93(d,J=4.4Hz,1H),6.82(d,J=4.4Hz,1H) ,6.33(t,J=5.5Hz,1H),5.40(d,J=5.8Hz,1H),4.71(t,J=5.3Hz,1H),4.37 -4.34(m,1H),4.25-4.20(m,2H),3.97-3.96(m,1H),3.81-3.78(m,1H),3. 75-3.69(m,2H),3.66-3.62(m,1H),3.15-3.10(m,1H),2.08-1.95(m,2H). 13 C NMR (151 MHz, DMSO-d 6 )δ150.1,148.4,124.0,117.4,117.1,110.8,101.3,81.6,81.5,79.5,74.5,70.7,70.6,69.8,69.7,67.8,63.9,63.8,43.4,29.5,29.4.

[0214] Example 19 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyltetrahydro-2H-pyran-4-carboxylate (A21)

[0215]

[0216] According to the method described in Example 18, tetrahydrofuran-3-carboxylic acid was replaced with tetrahydro-2H-pyran-4-carboxylic acid to synthesize compound A21 (0.96 g of white solid) with a total yield of 66.5% for two steps. 1 H NMR (600 MHz, DMSO-d 6)δ7.93(s,1H),7.90(br,1H),6.92(d,J=4.6Hz,1H),6.82(d,J=4.6Hz,1H),6.3 5(d,J=5.7Hz,1H),5.41(d,J=5.6Hz,1H),4.71(t,J=5.3Hz,1H),4.34-4.32(m, 1H),4.25-4.22(m,1H),4.19-4.16(m,1H),3.99-3.96(m,1H),3.79-3.77(m,2H ),3.33-3.29(m,2H),2.55-2.50(m,1H),1.68-1.63(m,2H),1.53-1.45(m,2H). 13 C NMR (151 MHz, DMSO-d 6 )δ156.2,148.5,124.0,117.4,117.1,110.7,101.2,81.6,79.4,74.5,70.6,66.5,63.3,28.8,28.7.

[0217] Example 20 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-cyclobutanecarboxylic acid)methyl ester (A22)

[0218]

[0219] According to the method described in Example 18, tetrahydrofuran-3-carboxylic acid was replaced with cyclobutylcarboxylic acid to synthesize compound A22 (0.7 g of white solid) with a total yield of 42% for two steps. 1 H NMR (400 MHz, DMSO-d 6 )δ7.93(s,1H),7.90(br,2H),6.93(d,J=4.5Hz,1H),6.80(d,J=4.5Hz,1H),6.34(d,J=5.9Hz,1H),5.38(d,J=5.8Hz,1H),4.68(t, J=5.2Hz,1H),4.35-4.31(m,1H),4.25-4.15(m,2H),3.96-3.92(m,1H),3.19-3.11(m,1H),2.15-2.09(m,4H),1.97-1.73(m,2H). 1 H NMR (101 MHz, DMSO-d 6)δ174.7,156.1,148.4,124.0,117.4,117.0,110.7,101.3,81.6,79.5,74.5,70.6,63.3,37.6,25.2,25.1,18.2.

[0220] Example 21 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-cycloheptanecarboxylic acid)methyl ester (A23)

[0221]

[0222] According to the method described in Example 18, tetrahydrofuran-3-carboxylic acid was replaced with cycloheptanecarboxylic acid to synthesize compound A23 (0.67 g of white solid) with a total yield of 36% for two steps. 1 H NMR (600 MHz, DMSO-d 6 )δ7.93(s,1H),7.90(br,1H),6.92(d,J=4.5Hz,1H),6.81(d,J=4.5Hz,1H),4.70(d,J=4.8Hz,1H),4.31-4.29(m,1H) ,4.24-4.22(m,1H),4.17-4.14(m,1H),3.97-3.95(m,1H),2.46-2.41(m,1H),1.80-1.77(m,2H),1.63-1.37(m,10H). 1 H NMR (151 MHz, DMSO-d 6 )δ176.1,156.1,148.4,124.1,117.4,117.0,110.6,101.2,81.7,79.4,74.6,70.6,63.1,60.2,44.4,30.7,30.6,28.2,28.1,26.2.

[0223] The obtained compounds are shown in Table 2 below.

[0224] Table 2

[0225]

[0226]

[0227]

[0228] Example 22: Metabolism of Compounds ATV014 and GS-441524 in Rats

[0229] 1. Dosage and method of administration for each group:

[0230] ATV014 intravenous injection group: 5 mg of ATV014 per kg of mouse body weight was intravenously injected;

[0231] ATV014 oral group: 25 mg ATV014 / kg mouse body weight was intragastrically administered;

[0232] GS-441524 intravenous injection group: 5 mg of GS-441524 per kg of mouse body weight was intravenously injected;

[0233] GS-441524 oral group: 25 mg of GS-441524 per kg of mouse body weight was administered intragastrically;

[0234] Among them, ATV014 is compound A10 prepared in Example 8.

[0235] 2. Operation:

[0236] 16 SD rats (male) weighing 220g-250g were divided into 4 groups, namely ATV014 intravenous injection group, ATV014 oral group, GS-441524 intravenous injection group, and GS-441524 oral group, with 4 rats in each group (3 rats in each ATV014 group), and the drugs were administered according to "1. Dosage and administration method of each group". Blood was collected from the jugular vein. About 0.3mL of blood was collected into heparin tubes at 0.083h (no blood was collected in the oral group), 0.16h (no blood was collected in the oral group), 0.25h, 0.5h, 1h (no blood was collected in the intravenous injection group), 2h, 4h, 8h, 24h, and 48h after administration, and centrifuged at 4000r / min for 10min at 4, and the upper plasma was transferred to a refrigerator (about -20) for temporary storage until the measurement. Take 50 μL plasma sample, add 100L 90% methanol aqueous solution, vortex mix; then add 350 μL methanol acetonitrile mixed solution (1:1, V / V), vortex mix; centrifuge at 10000rpm for 10min, take the supernatant and filter it through 0.22μm filter membrane before sampling and detection; blood samples taken 0.5 hours after intravenous administration and 4 hours after oral administration were diluted 10 times and then sampled for detection. The drug concentration in each sample was determined by high performance liquid chromatography (HPLC) / mass spectrometry (MS). Waters UPLC / XEVO TQ-S column and InertSustain AQ-C18HP column (3.0mm×50mm,3.0μm,GL) were used to separate the analytes. DAS (Drug and Statistics) 3.0 software was used to calculate the pharmacokinetic parameters.

[0237] Results: See Tables 3, 4 and Figure 1 .

[0238] Table 3 Pharmacokinetic parameters of SD rats after administration of ATV014 (detection of GS-441524, mean ± SD, n = 3)

[0239]

[0240] Table 4 Pharmacokinetic parameters of SD rats after administration of GS-441524 (mean ± standard deviation, n = 4)

[0241]

[0242] in conclusion:

[0243] From Table 3, Table 4 and Figure 1 It can be seen that the oral bioavailability of ATV014 is 49.08%, and the oral bioavailability of GS-441524 is 22.63%, indicating that compared with GS-441524, the oral bioavailability of ATV014 is significantly improved and has better oral drugability.

[0244] Example 23: Antiviral Activity Test of Compounds on Vaccinia Virus

[0245] The anti-pox virus activity of the compound was first tested using vaccinia virus (classified as the same genus as monkeypox virus), which is closely related to monkeypox virus, as a surrogate virus. The anti-vaccinia virus activity test was carried out in a BSL-2 laboratory. VERO cells were infected with vaccinia virus, with a simulated infection dose of MOI = 1 and an infection time of 24 hours. The genome was extracted to determine the template dosage and test the primer sensitivity. The cells were collected and the genome was extracted. Virus replication was detected by qPCR to detect the drug inhibitory effect of the prepared solution. The experiment was repeated three times. At the same time, the toxicity of the virus and the inhibitor to the cells themselves was carefully observed. The results are as follows: Figure 2 and Figure 3 The test groups are as follows:

[0246] 1MOL group: solvent control (negative control group);

[0247] Group 1: terwilima (positive control group);

[0248] Group 2: bromxifovir (positive control group);

[0249] Group 10: cidofovir (positive control group);

[0250] Group 36: Compound ATV014;

[0251] Antiviral activity of different compounds against vaccinia virus in Vero cells Figure 2 shown.

[0252] References: Poyot T, et al., J Virol Methods. 2012 Dec; 186(1-2): 176-83; Rico AB, et al., J Virol. 2019 Sep 30; 93(20): e00855-19.

[0253] The specific operations are as follows:

[0254] 1. Virus infection:

[0255] Inoculate 1.5*10^5 / well VERO cells / well in a 24-well plate, culture overnight, replace 2% FBSDMEM medium after the cells adhere to the wall, add MOI of 1AVAC to each well 1 hour after adding drugs, infect for 24 hours, and observe the cell status. Note the drug solvent (DMSO, D2O), the control group is treated with DMSO.

[0256] 2. Cell collection and genome extraction:

[0257] Collect the culture medium supernatant into a 1.5EP tube, centrifuge at 3000g for 5min, remove the supernatant, use 500μL of trypsin to digest the cells for 3min, add 500μL of DMEM to neutralize, centrifuge at 1000g for 5min, and extract genomic DNA from the cells (tiangen blood / cell / tissue genomic DNA extraction kit DP304-03).

[0258] 3. qPCR detection of viral replication:

[0259] Genomic DNA was used as a template, and the template dosage was determined through preliminary experiments to be: 10 ng genome, and the primer concentration was: 0.4 μM.

[0260] 4. The drugs with preliminary effects detected above (1μM, 5μM or 10μM) were further verified with screening concentrations of 0.01μM, 0.1μM, 1μM, and 10μM. The reason why drug No. 2, bromsifovir, was used at 5μM instead of 10μM is that its maximum solubility is 1mM in DMSO.

[0261] Primer sequences:

[0262] orthopox consensus genus primers(J Virol Methods.2012)

[0263] VACV-F:5_-GCCAGAGATATCATAGCCGCTC-3 (SEQ ID NO:1);

[0264] VACV-R:5_-CAACGACTAACTAATTTGGAAAAAAAGAT-3 (SEQ ID NO: 2);

[0265] VACV primers 2 (J Virol, 2019)

[0266] VACV-FHA:5=-CATCATCTGGAATTGTCACTACTAAA-3=(SEQ ID NO:3);

[0267] VACV-RHA:5=-ACGGCCGACAATTATAATTAATGC-3=(SEQ ID NO:4);

[0268] (NCBI-BLAST-getPrimer)

[0269] VERO-gDNA:

[0270] 5_-GGCTCCGAATTATGACCAACATC-3 (SEQ ID NO: 5);

[0271] 5_-CCAGTTACCGCTCCCTGACATAGTG-3 (SEQ ID NO: 6);

[0272] VERO-tert-F:TCACGGAGACCACGTTTCAG (SEQ ID NO:7);

[0273] VERO-tert-R: GCCCATCACATCCACCTTGA (SEQ ID NO: 8);

[0274] VERO-tert-2F: CCGTCGTCATTGAGCAGAGT (SEQ ID NO: 9);

[0275] VERO-tert-2R: ACACGAAGCGTAGGAAGACG (SEQ ID NO: 10).

[0276] test Figure 2 The results showed that compared with the solvent group, except for tewima, the other three compounds of the four tested compounds could effectively reduce the level of vaccinia virus DNA replication at the two tested concentrations (1μM, 5μM or 10μM). The anti-pox virus activity of compound ATV014 at high concentration was better than that of the other three marketed drugs. In further IC 50 Testing Figure 3 ), IC of compound ATV014 50reached 8nM, while the IC of the control drug cidofovir 50 The compound ATV014 showed significant anti-pox virus activity in cell experiments, which was 912 times more active than cidofovir.

[0277] Example 24: Antiviral activity test of compounds on monkeypox virus

[0278] The activity test of compound ATV014 against monkeypox virus was carried out in a BSL-3 laboratory. First, the test drug was prepared into a mother solution with DMSO, and then diluted to 100 μM using 2% FBS DMEM medium. Vero-E6 cells were infected with monkeypox virus, the infection dose was about MOI = 0.05, the infection time was 1 hour, and then washed once with PBS, and 2% FBSDMEM medium containing 100 μM test drug was added and cultured for 48 hours. Then the cells and supernatant were collected by freeze-thaw method, the genome was extracted, and the virus replication was detected by qPCR to detect the effect of the drug on inhibiting monkeypox virus. The experiment was repeated three times. At the same time, the toxicity of the virus and the inhibitor to the cells themselves was carefully observed. The test group includes the following groups:

[0279] Ctrl group: solvent control (negative control group)

[0280] Group B10: Cidofovir (positive control group)

[0281] Group A1: Remdesivir (positive control group);

[0282] Group A2: GS-441524;

[0283] Group A3: Compound A3;

[0284] Group A4: Compound A4;

[0285] Group A5: Compound A5;

[0286] Group A6: Compound A6;

[0287] Group A7: Compound A7;

[0288] Group A8: Compound A8;

[0289] Group A9: Compound A9;

[0290] Group A10: Compound A10 (ATV014);

[0291] Group A11: compound A11 (ATV014D);

[0292] Group A12: Compound A12 (A-ATV014);

[0293] Group A13: Compound A13.

[0294] The specific operations are as follows:

[0295] 1. Inoculate 6×10 cells in a 24-well plate 18 hours in advance. 4 Vero-E6 cells / well, cultured overnight.

[0296] 2. Bring the 24-well plate cells cultured overnight into the BSL-3 laboratory, add monkeypox virus at MOI = 0.05 to each well, and infect at 37 for 1 hour.

[0297] 3. Take out the 24-well plate, add 500 μL of PBS to each well, let it stand for 5 minutes, and then aspirate and discard the PBS.

[0298] 4. Add 500 μL of DMEM containing 2% FBS containing 100 μM of the drug to be tested and infect at 37 for 48 hours.

[0299] 5. Take the cells cultured for 48 hours out of the cell culture incubator and put them in a -80 refrigerator for 20 minutes. Then take the cells out of the -80 refrigerator and put them in a 37 cell culture incubator for 20 minutes. Repeat this freeze-thaw process twice.

[0300] 6. Place the twice frozen and thawed cells in a biosafety cabinet, mix them evenly with a pipette, and take 200 μL for nucleic acid extraction.

[0301] 7. Use the Daan Gene Nucleic Acid Extraction Kit (#DA0620) to extract nucleic acid from the sample.

[0302] 8. Take 10 μl of the extracted nucleic acid and dilute it to 50 μl with double distilled water to use as a template for qPCR detection.

[0303] 9. Design of monkeypox virus primers: mix the upstream primer and the downstream primer together to a final concentration of 1 μM.

[0304] F3L-Fcttccgtcaatgtctacacaggc(SEQ ID NO:11)

[0305] F3L-R cgttggtctacgacaatggatgc(SEQ ID NO:12)

[0306] 10. Use Novozyme SYBR Green Mixture (#Q712) to detect the content of the target nucleic acid fragment in the sample. Prepare the reaction system according to Table 5 and run the qPCR program according to Table 6.

[0307] Table 5 qPCR reaction system

[0308]

[0309]

[0310] Table 6 qPCR reaction procedure

[0311]

[0312] 11. Data processing and analysis. Taking the monkeypox virus DNA content of the control group as 1, the monkeypox virus DNA content of the drug group was compared with that of the control group, and the vertical axis was converted into a -log form. The antiviral activity of different compounds against monkeypox virus in Vero-E6 cells was shown in Figure 4 shown.

[0313] The test results showed that compared with the solvent group, the four tested compounds, except for tewirima, cidofovir, remdesivir, ATV014 and ATV014D, could effectively reduce the level of monkeypox virus DNA replication under the tested 100μM conditions. Among them, the anti-monkeypox virus activity of compounds ATV014 and ATV014D at high concentrations was better than that of the other two drugs.

[0314] Using the same method and steps, the IC50 of cidofovir, remdesivir, ATV014 and ATV014D for inhibiting monkeypox virus was tested. The four compounds were diluted 5 times in DMEM medium containing 2% FBS to prepare 6 concentration gradients, namely 100 μM, 20 μM, 4 μM, 0.8 μM, 0.16 μM, and 0.032 μM.

[0315] Using the above method, the cells and supernatants of the drug group and the control group were collected, the genome was extracted, and the virus replication was detected by qPCR to detect the effect of the drug on inhibiting monkeypox virus. The experiment was repeated three times.

[0316] The antiviral activity of the drug is calculated as follows:

[0317] Inhibition rate (%) = (average copy number of virus control - average copy number after drug treatment) / (average copy number of virus control) × 100

[0318] GraphPad Prism (version 8) was used to perform nonlinear fitting analysis on the inhibition rate of the drug and calculate the half effective concentration (IC 50 ) value. The fitting formula is: log(inhibitor) vs. response-Variable slope. The inhibition curves of different compounds on monkeypox virus in Vero-E6 cells are shown in Figure 5 shown.

[0319] The experimental results show that the IC values ​​of the tested samples ATV014 and ATV014D for the tested monkeypox virus are 50 The values ​​were 3.2μM and 2.5μM respectively; the positive drugs remdesivir and cidofovir had IC values ​​for the tested monkeypox virus 50 The values ​​were 85.8μM and 41.6μM. ATV014 and ATV014D were superior to the positive control groups of remdesivir and cidofovir. ATV014 had a good inhibitory effect on monkeypox virus in the cell infection model.

[0320] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.

Claims

1. Use of a nucleoside compound in the preparation of an anti-orthopoxvirus-related product, wherein the nucleoside compound is a compound of the following formula or a pharmaceutically acceptable salt thereof: , , The anti-orthopoxvirus related products can be used to prevent, alleviate or treat diseases caused by orthopoxvirus infection; The orthopoxvirus genus includes smallpox virus, vaccinia virus, mousepox virus, monkeypox virus, rabbitpox virus, cowpox virus and horsepox virus.

2. The use according to claim 1, characterized in that The infection includes any one of skin lesions, fever, headache, fatigue, muscle aches, superficial lymphadenopathy, coma, edema and multiple organ failure.

3. Use of a pharmaceutical composition in the preparation of an anti-orthopoxvirus-related product, characterized in that: The pharmaceutical composition comprises the nucleoside compound used in claim 1 and a pharmaceutically acceptable carrier; The anti-orthopoxvirus related products can be used to prevent, alleviate or treat diseases caused by orthopoxvirus infection; The orthopoxvirus genus includes smallpox virus, vaccinia virus, mousepox virus, monkeypox virus, rabbitpox virus, cowpox virus and horsepox virus.

4. The use according to claim 3, characterized in that The pharmaceutical composition is in the form of tablets, pills, creams, emulsions, ointments, suspensions, lyophilized preparations, capsules, sustained-release preparations, granules, granules, injections or sprays.

5. The use according to claim 3 or 4, characterized in that: The products are suitable for use on humans or animals.

6. The use according to claim 5, characterized in that The animals include bovines, equines, ovines, porcines, canines, felines, lagomorphs, avian animals, rodents or primates.